You are here

Home » Content

Polisiteminin Nadir bir Nedeni: İdiyopatik Pulmoner Arteriyel Hipertansiyon

A Rare Cause of Polycythemia: Idiopathic Pulmonary Arterial Hypertension

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2011

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
Idiopathic pulmonary arterial hypertension (IPAH) with an incidence of 1-2/million per-year. IPAH is a term used to define a variety of progressive conditions that have in common, increased pulmonary vascular resistance leading to right heart failure and death. Pulmonary arterial hypertension is presented with cyanosis, polyctemia and right heart failure. Increased prevelance of mortality is due to progression and late diagnosis of the disease. We present this case to alert physicians to keep in mind rare but serious disease IPAH in the differential diagnosis of polyctemia.
Bookmark/Search this post with
Abstract (Original Language): 
İdiyopatik pulmoner arteriyel hipertansiyon (İPAH), yıllık insidansı 1-2/milyon olan oldukça nadir görülen, tedavi edilmediğinde hızlı bir seyirle sağ kalp yetmezliği ve ölüme kadar giden morbidite ve mortalitesi yüksek bir hastalıktır. Klinik bulgular tüm pulmoner hipertansiyon tiplerinde olabileceği gibi siyanoz, polisitemi ve sağ kalp yetmezliği belirtileri ile seyredebilir. Mortalitenin yüksek olması, hastalığın seyrinden ve tanının sıklıkla geç evrede konmasından kaynaklanmaktadır. Bu vakayı, özellikle genç yaşta olan olgularda polisitemi etyolojisi araştırılırken nadir görülen İPAH hastalığına dikkat çekmek için sunduk.
FULL TEXT (PDF): 
PDF icon arastirmax-polisiteminin-nadir-bir-nedeni-idiyopatik-pulmoner-arteriyel-hipertansiyon.pdf
  • 3
177-178
  • Turkish

REFERENCES

References: 

1. Kayıkcıoğlu M, Kültürsay H. İdiyopatik Pulmoner Hipertansiyon. Turkiye Klinikleri J Cardiol-Special Topics 2010;3(1):48-6.
2. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-49.
3. Humbert M, Nunes H, Sitbon O, Parent F, Herve P, Simonneau G. Risk factors for pulmonary arterial hypertension Clin Chest Med 2001;22:459-75.
4. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173(9):1023-30.
5. Simonneau G, Robbins I, Beghetti M, Channick RN, Delcroix M, Denton CP,Elliott CG, Gaine S, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension.J Am Coll Cardiol
2009;54:S43-54.
6. Peacock AJ, Murphy NF, McMurray JJV, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30:104-9.
7. Chaouat A, Bugnet AS, Kadaoui N, et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:189-94.
8. Harari S, Simonneau G, De Juli E, et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997;16:460-3.
9. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001;120:801-8.

Thank you for copying data from http://www.arastirmax.com